Interestingly, when looking at KRAS and TP53 comutations, there were higher percentage of KRAS and TP53 comutations in HR- NSCLC, particularly in females (HR+: 40.65% vs. HR-: 54.10%, p<0.0001, q =<0.0001) (Table 5). This evidence concerns the gene KRAS and non-small cell lung carcinoma.